Vascular cell responsiveness to Toll-like receptor ligands in carotid atheroma.
BACKGROUND
Atherosclerosis is potentiated by stimulation of Toll-like receptors (TLRs), which serve to detect pathogen associated molecular patterns (PAMPs). However little is known of which PAMPs may be present in atheroma, or capable of stimulating inflammatory signalling in vascular cells.


METHODS
DNA extracted from human carotid atheroma samples was amplified and sequenced using broad-range 16S gene specific primers to establish historical exposure to bacterial PAMPs. Responsiveness of primary human arterial and venous endothelial and smooth muscle cells to PAMPs specific for each of the TLRs was assessed by measurement of interleukin-8 secretion and E-selectin expression.


RESULTS
Extracts of atheromatous tissue stimulated little or no signalling in TLR-transfected HEK-293 cells. However, sequencing of bacterial DNA amplified from carotid atheroma revealed the presence of DNA from 17 different bacterial genera, suggesting historical exposure to bacterial lipopeptide, lipopolysaccharide and flagellin. All cells examined were responsive to the ligands of TLR3 and TLR4, poly inosine:cytosine and lipopolysaccharide. Arterial cells were responsive to a wider range of PAMPs than venous cells, being additionally responsive to bacterial flagellin and unmethylated cytosine-phosphate-guanosine DNA motifs, the ligands of TLR5 and TLR9, respectively. Cells were generally unresponsive towards the ligands of human TLR7 and TLR8, loxoribine and single stranded RNA. Only coronary artery endothelial cells expressed TLR2 mRNA and responded to the TLR2 ligand Pam(3)CSK(4).


CONCLUSIONS
Vascular cells are responsive to a relatively diverse range of TLR ligands and may be exposed, at least transiently, to ligands of TLR2, TLR4, TLR5 and TLR9 during the development of carotid atheroma.
Erridge
C
C
Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, UK. ce55@leicester.ac.uk
Burdess
A
A
Jackson
A J
AJ
Murray
C
C
Riggio
M
M
Lappin
D
D
Milligan
S
S
Spickett
C M
CM
Webb
D J
DJ
D000942:Antigens, Bacterial / Q000276:immunology / Q000494:pharmacology*; D015415:Biomarkers / Q000032:analysis; D002340:Carotid Artery Diseases / Q000276:immunology / Q000378:metabolism*; D002460:Cell Line; D017931:DNA Primers / Q000235:genetics; D004269:DNA, Bacterial / Q000032:analysis; D019040:E-Selectin / Q000032:analysis; D042783:Endothelial Cells / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D016209:Interleukin-8 / Q000032:analysis; D008024:Ligands; D032389:Myocytes, Smooth Muscle / Q000276:immunology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D017422:Sequence Analysis, DNA; D051195:Toll-Like Receptor 2 / Q000235:genetics / Q000378:metabolism; D051197:Toll-Like Receptor 4 / Q000235:genetics / Q000378:metabolism; D051198:Toll-Like Receptor 5 / Q000235:genetics / Q000378:metabolism; D051217:Toll-Like Receptor 9 / Q000235:genetics / Q000378:metabolism; D051193:Toll-Like Receptors / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D014162:Transfection / Q000379:methods
D000942:Antigens, Bacterial; D015415:Biomarkers; D017931:DNA Primers; D004269:DNA, Bacterial; D019040:E-Selectin; D016209:Interleukin-8; D008024:Ligands; D051195:Toll-Like Receptor 2; D051197:Toll-Like Receptor 4; D051198:Toll-Like Receptor 5; D051217:Toll-Like Receptor 9; D051193:Toll-Like Receptors